Prevention of influenza, especially in people exposed to post-influenza complications. The Vaxigrip vaccine is indicated for adults and children from the age of 6 months. The use of the vaccine should be in accordance with official recommendations.
Composition:
1 dose (0.5 ml) contains the split, inactivated influenza virus of the following strains: A (H1N1) - 15 μg HA, A (H3N2) - 15 μg HA and B - 15 μg HA (HA - haemagglutinin). The vaccine complies with the WHO recommendations (for the northern hemisphere) and the EU decision for the current season.
Action:
Influenza vaccine (split virion), inactivated. Resistance occurs after 2-3 weeks. Resistance to homologous strains to those contained in the vaccine or to related strains is usually maintained for 6-12 months.
Contraindications:
Hypersensitivity to active substances, excipients or residues after the production process (egg albumin, chicken protein, neomycin, formaldehyde, 9-octoxynol). Disease with fever or acute infection (vaccination should be postponed). Do not give intravascularly.
Precautions:
In patients with congenital or acquired immunodeficiency, the immune response may be insufficient. The safety and efficacy of Vaxigrip in children under 6 months has not been established.
Pregnancy and lactation:
Inactivated influenza vaccines can be given in all periods of pregnancy. A larger set of safety data is available for the second and third trimesters compared to the first trimester; however, data from around the world regarding the use of inactivated influenza vaccines do not indicate any adverse effects on the mother and fetus associated with the vaccine. The vaccine can be used during breastfeeding.
Side effects:
Common: headache, sweating, muscle pain, joint pain, fever, feeling unwell, chills, tiredness, reactions at the injection site (redness, swelling, pain, bruising, induration). In addition, there may be: transient thrombocytopenia, transient lymphadenopathy, allergic reactions (in rare cases leading to shock, angioneurotic edema), neuralgia, paraesthesia, febrile convulsions, neurological disorders (encephalomyelitis, neuritis, Guillan-Barré syndrome) , generalized skin reactions (including pruritus, urticaria, rash), inflammation of the blood vessels connected in very rare cases with transient renal dysfunction.
Dosage:
Intramuscularly or deeply subcutaneously. Adults and children from 36 years old: 0.5 ml; children from 6 to 35 months old: clinical data are limited, doses of 0.25 ml or 0.5 ml can be administered. The dose used should be in line with existing national recommendations. For children who have not been vaccinated before, the second dose should be given after at least 4 weeks.
(C)
